Page 12 - Trepl News Today : Breaking News, Live Updates & Top Stories | Vimarsana

…

A number of firms have modified their ratings and price targets on shares of Replimune Group (NASDAQ: REPL) recently: 5/25/2022 – Replimune Group was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes […]

Replimune Group, Inc. (NASDAQ:REPL – Get Rating) – Analysts at Wedbush issued their FY2024 earnings per share estimates for shares of Replimune Group in a research note issued to investors on Tuesday, May 24th. Wedbush analyst R. Driscoll anticipates that the company will earn ($2.77) per share for the year. Wedbush currently has a “Outperform” […]

Replimune Group (NASDAQ:REPL – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of […]

Replimune Group (NASDAQ:REPL – Get Rating) had its price target reduced by Piper Sandler from $52.00 to $44.00 in a report issued on Thursday, The Fly reports. Piper Sandler’s price objective would suggest a potential upside of 201.16% from the stock’s previous close. A number of other brokerages have also recently commented on REPL. BMO […]